Results 131 to 140 of about 38,898 (237)

Guidance for Documentation of Therapeutic Apheresis Interventions in the Medical Record: An American Society for Apheresis (ASFA) Practice Perspective

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 2, April 2026.
ABSTRACT In 2007, the American Society for Apheresis (ASFA) published guidance for physician documentation related to oversight of therapeutic apheresis (TA). Due to 21st century changes in healthcare delivery, the ASFA Board of Directors (BOD) charged its Public Affairs and Advocacy Committee (PAAC) to coordinate a review and update of the guidance ...
Chester Andrzejewski   +8 more
wiley   +1 more source

Clinical efficacy of a novel autologous blood recovery device during ECMO weaning

open access: yesZhongguo shuxue zazhi
[Objective] To evaluate the clinical efficacy of a novel autologous blood recovery device during the weaning process from extracorporeal membrane oxygenation (ECMO).
LU Yufeng   +5 more
doaj   +1 more source

Twenty Years of Therapeutic Leukocytapheresis in Newly Diagnosed Acute Myeloid Leukemia: Insights From A Single Center

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 2, April 2026.
ABSTRACT Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, and 5%–20% of newly diagnosed patients present with hyperleukocytosis (HL). HL, most often defined as WBC > 100 000/μL, is a hematologic emergency associated with severe complications, early mortality, and poor prognosis, requiring immediate intervention.
Vojtech Latal   +10 more
wiley   +1 more source

Multiday Use of Non‐Tunneled Central Venous Catheters in Vetted Adult Outpatients Undergoing Apheresis Collections of Autologous Peripheral Blood Stem Cells Is Feasible and Well Tolerated

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 2, April 2026.
ABSTRACT Autologous peripheral blood stem cell (PBSC) collections are routinely performed in the outpatient setting and typically involve placement of an apheresis‐compatible central venous catheter (CVC). There is reluctance to discharge outpatients with non‐tunneled CVCs due to safety concerns.
Andres E. Mindiola Romero   +4 more
wiley   +1 more source

Repeated injection of pooled frozen allogeneic umbilical cord blood mesenchymal stromal cells in 5 flat‐racing horses

open access: yesEquine Veterinary Education, Volume 38, Issue 4, Page 183-194, April 2026.
Summary Background Tendinopathies in racehorses are challenging to treat, and restoring normal tendon composition remains elusive despite extensive research. Equine multipotent mesenchymal stromal cells (MSC) have shown promise for tendon repair, and various sources of MSC have been described.
A. Merchan Muñoz   +7 more
wiley   +1 more source

Investigation on the mechanisms of action of aprotinin in cardiac surgery [PDF]

open access: yes, 1991
Baranky, A.   +8 more
core   +1 more source

Molecular Testing in Sickle Cell Disease: From Newborn Screening to Transfusion Care

open access: yesInternational Journal of Laboratory Hematology, Volume 48, Issue 2, Page 295-304, April 2026.
ABSTRACT Sickle cell disease (SCD) is one of the most frequent monogenic diseases worldwide and a highly heterogeneous and complex disease. SCD care carries several challenges. This includes early and accurate diagnosis as well as optimal red blood cell transfusion matching in this population carrying a high risk of alloimmunization.
Thomas Pincez, Yves D. Pastore
wiley   +1 more source

Effect of retransfusion of heparin remaining in the salvaged blood on postoperative blood loss in coronary artery bypass grafting: Comparison with homologous blood transfusion (running title: Postoperative blood loss in CABG) [PDF]

open access: yes, 2012
Background: One of the typical problems of cell savers is the retransfusion of the heparin added to the system. The aim of this study was to determine whether or not heparin, remaining in the prepared sample of retransfusion blood, might be responsible ...
Aghdaii, Nahid.   +3 more
core  

Research Progress on Platelet‐Rich Plasma (PRP) in the Treatment of Androgenetic Alopecia

open access: yesJournal of Cosmetic Dermatology, Volume 25, Issue 4, April 2026.
ABSTRACT Background Androgenetic alopecia (AGA) is the most common cause of progressive hair loss, significantly affecting quality of life. Current therapies, such as minoxidil, finasteride, and hair transplantation, show variable efficacy and may be associated with adverse effects.
Zetian Zhong   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy